H.C. Wainwright lowered the firm’s price target on Splash Beverage (SBEV) to 50c from $1 and keeps a Buy rating on the shares ...

The Company clarified that they are not obligated to sell any Shares under this agreement. H.C. Wainwright & Co., LLC will act to sell the Shares based on electroCore’s instructions and within the ...

Ardelyx (NASDAQ:ARDX) shares were down over 5% after H.C. Wainwright downgraded the rating for the biopharmaceutical firm, ...

H.C. Wainwright maintains a Buy rating and 12-month price target of $11 on CollPlant (CLGN) shares after the company reported Q3 results and ...

H.C. Wainwright adjusted the firm’s price target on Arqit Quantum (ARQQ) to $22 from $2 and keeps a Buy rating on the shares to reflect the ...

WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage ...

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Alector (ALEC) to $7 from $35 and keeps a Buy rating ...

H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $49 from $43 and keeps a Buy rating on the shares. Acoramidis received regulatory approval with the label underscoring ...

H.C. Wainwright analyst Douglas Tsao reiterates a Buy rating on Biohaven (BHVN) after taldefgrobep alfa missed in Phase 3 for spinal muscular atrophy. Perhaps the more important commercial finding ...

Phunware (NASDAQ:PHUN) shares retreated 11% in Tuesday late morning trading after H.C. Wainwright & Co. downgraded the application software company to Neutral from Buy, as analyst Scott Buck ...

Ardelyx (NASDAQ:ARDX) shares were down over 5% after H.C. Wainwright downgraded the rating for the biopharmaceutical firm, saying that it anticipates a substantial drop in the company's kidney ...